Levomilnacipran

Brand names: Fetzima · Active ingredient: Levomilnacipran Hydrochloride

In short: FETZIMA® is indicated for the treatment of major depressive disorder (MDD) in adults . Limitation of Use: FETZIMA is not approved for the management of fibromyalgia.

Forms & strengthsFETZIMA (levomilnacipran) is available as 20 mg, 40 mg, 80 mg, and 120 mg extended-release capsules. Capsule Strength | Capsule Color/Shape | Capsule Markings 20 mg | yellow capwhite body | black "FL" on capblack "20" on body 40 mg | yellow capyellow body | …
LabelAllergan, Inc.
Label updatedFeb 23, 2026

What is Levomilnacipran used for?

FETZIMA® is indicated for the treatment of major depressive disorder (MDD) in adults .

Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established.

⚠ Boxed warning (FDA's strongest warning)

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors

.

FETZIMA is not approved for use in pediatric patients

.

Levomilnacipran dosage

The recommended dosage range for FETZIMA is 40 mg to 120 mg once daily, with or without food. FETZIMA should be initiated at 20 mg once daily for 2 days and then increased to 40 mg once daily. Based on clinical response and tolerability, FETZIMA may be increased in increments of 40 mg at intervals of 2 or more days. The maximum recommended dosage is 120 mg once daily.

Take FETZIMA at approximately the same time each day. Swallow FETZIMA whole; do not open, chew, or crush the capsule.

Prior to initiating treatment with FETZIMA or another antidepressant, screen patients for a personal or family history of bipolar disorder, mania, or hypomania .

End stage renal disease (ESRD): FETZIMA is not recommended;

Severe renal impairment (creatinine clearance of 15 to 29 mL/min), the dosage should not exceed 40 mg once daily;

Moderate renal impairment (creatinine clearance of 30 to 59 mL/min), the dosage should not exceed 80 mg once daily;

Mild renal impairment (creatinine clearance of 60 to 89 mL/min): no dosage adjustment recommended .

Discontinuation symptoms have been reported with discontinuation of serotonergic drugs such as FETZIMA. Gradual dose reduction is recommended, instead of abrupt discontinuation, whenever possible. Monitor patients for these symptoms when discontinuing FETZIMA. If intolerable symptoms occur following a dose decrease or upon discontinuation of treatment, consider resuming the previously prescribed dose and decreasing the dose at a more gradual rate .

At least 14 days must elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with FETZIMA. Conversely, at least 7 days should be allowed after stopping FETZIMA before starting an MAOI antidepressant .

The maximum recommended dosage of FETZIMA should not exceed 80 mg once daily when used with strong CYP3A4 inhibitors [

s

ee Drug Interactions (

7.1

)]

.

How to take Levomilnacipran — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Suicide Thoughts and Behaviors

Advise patients and caregivers to look for the emergence of suicidal thoughts and behaviors, especially early during treatment and when the dose is adjusted up or down, and instruct them to report such symptoms to the healthcare provider .

Dosing and Administration

Advise patients that FETZIMA should be swallowed whole and should not be chewed, crushed, or opened.

Advise patients that FETZIMA can be taken with or without food.

Instruct patients if they miss a dose, to take the missed dose as soon as they remember. If it is almost time for the next dose, instruct them to skip the missed dose and take their next dose at the regular time. Advise them not to take two doses of FETZIMA at the same time.

Concomitant Medication

Instruct patients not to take FETZIMA with an MAOI or within 14 days of stopping an MAOI and to allow 7 days after stopping FETZIMA before starting an MAOI . Advise patients to inform their physician if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for drug-drug interactions

. …

Warnings & precautions

Do not take this medicine if: FETZIMA is contraindicated:

in patients with hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in the formulation.

with the use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA is contraindicated because of an increased risk of serotonin syndrome. The use of FETZIMA within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated .

Starting FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome .

In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients aged 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 1.

Age Range | Drug-Placebo Difference in Number of Patients of Suicidal Thoughts or Behaviors per 1000 Patients Treated

Increases Compared to Placebo

<18 years old | 14 additional patients

18-24 years old | 5 additional patients

Decreases Compared to Placebo

25-64 years old | 1 fewer patient

≥65 years old | 6 fewer patients

*Fetzima is not approved for use in pediatric patients. …

Levomilnacipran side effects

The following adverse reactions are discussed in greater detail in other sections of the label.

Hypersensitivity

Suicidal Thoughts and Behaviors in Adolescents and Young Adults

Serotonin Syndrome

Elevated Blood Pressure

Elevated Heart Rate

Increased Risk of Bleeding

Angle Closure Glaucoma

Urinary Hesitation or Retention

Activation of Mania/Hypomania

Seizure

Discontinuation Syndrome

Hyponatremia

Sexual Dysfunction

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.

Patient

e

xposure

The safety of FETZIMA was evaluated in 3,317 patients (18 to 78 years of age) diagnosed with MDD who participated in clinical studies, representing 1,186 patient-years of exposure. Among the 3,317 FETZIMA-treated patients, 1,583 were exposed to FETZIMA in short-term, placebo-controlled studies. There were 825 patients who continued from short-term studies into a one-year, open-label extension study.

Of the 3,317 patients exposed to at least one dose of FETZIMA, 895 patients were exposed to FETZIMA for at least 6 months and 367 were exposed for one year. In these studies, FETZIMA was given at doses ranging from 40 mg to 120 mg once daily and was given without regard to food. …

Drug interactions

Table 5 includes clinically important drug interactions with FETZIMA.

Monoamine Oxidase Inhibitors (MAOIs)

Clinical Impact: | Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome.

Intervention: | Concomitant use of FETZIMA is contraindicated:

With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA.

Within 14 days of stopping an MAOI intended to treat psychiatric disorders

In a patient who is being treated with linezolid or intravenous methylene blue

[see Dosage and Administration (

2.5

,

2.6

), Contraindications (

4

), and Warnings and Precautions (

5.2

)].

Examples: | selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue

Other Serotonergic Drugs

Clinical Impact: | Concomitant use of FETZIMA with other serotonergic drugs increases the risk of serotonin syndrome.

Intervention: | Monitor for symptoms of serotonin syndrome when FETZIMA is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, immediately discontinue FETZIMA and/or concomitant serotonergic drugs [

see Dosage and Administration

(

2.5

,

2.6

), Contraindications (

4

), and Warnings and Precautions

(

5.2

)

]. …

About this medicine

FETZIMA contains levomilnacipran, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), in the form of hydrochloride salt with the chemical name of levomilnacipran hydrochloride is (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride. Its empirical formula is C15H2

2N2O∙HCl and its molecular weight is 282.8 g/mol. Levomilnacipran (Initial US approval: 2013) is the 1S,2R-enantiomer of milnacipran. The chemical structure of levomilnacipran hydrochloride is:

FETZIMA extended-release capsules are intended for oral administration. Each FETZIMA capsule contains 23.0, 45.9, 91.8, or 137.8 mg of levomilnacipran hydrochloride equivalent to 20, 40, 80, or 120 mg of levomilnacipran, respectively.

Inactive ingredients include ethylcellulose, hypromellose, povidone, sugar spheres, talc, titanium dioxide, and triethyl citrate. Inactive ingredients also include black iron oxide, red iron oxide (80 mg and 120 mg capsules only), shellac glaze, and yellow iron oxide (20 mg and 40 mg capsules only). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f371258d-91b3-4b6a-ac99-434a1964c3af. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone